242 related articles for article (PubMed ID: 11396980)
1. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. Characterization of aberrant FHIT transcripts in gastric adenocarcinomas.
Lee SH; Kim CJ; Park HK; Koh JW; Cho MH; Baek MJ; Lee MS
Exp Mol Med; 2001 Sep; 33(3):124-30. PubMed ID: 11642547
[TBL] [Abstract][Full Text] [Related]
4. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
[TBL] [Abstract][Full Text] [Related]
5. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
[TBL] [Abstract][Full Text] [Related]
6. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
7. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
9. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
11. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
[TBL] [Abstract][Full Text] [Related]
12. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
13. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
[TBL] [Abstract][Full Text] [Related]
14. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
15. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
16. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities of the FHIT gene in human oral carcinogenesis.
Tanimoto K; Hayashi S; Tsuchiya E; Tokuchi Y; Kobayashi Y; Yoshiga K; Okui T; Kobayashi M; Ichikawa T
Br J Cancer; 2000 Feb; 82(4):838-43. PubMed ID: 10732756
[TBL] [Abstract][Full Text] [Related]
18. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
[TBL] [Abstract][Full Text] [Related]
20. [Association of fragile histidine triad gene (FHIT) with susceptibility to esophageal cancer. A preliminary study].
Li W; Wang X; Cheng G
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):258-60. PubMed ID: 10920977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
